Eli Lilly’s GLP-1 pill helped some participants lose up to 15% body weight. But is it as effective as the injection? Here's ...

An observational study of 160,000 patients with diabetes taking GLP-1 drugs finds no heightened risk for retinopathy ...

A new study in mice has found that muscle loss associated with weight loss from GLP-1 medications like Ozempic may not be as ...

In the first Phase 3 trial of its once-daily oral GLP-1 pill in people with obesity, drugmaker Eli Lilly said Thursday that ...

A former college athlete, 51-year-old Charles never thought he'd have to worry about his weight. But football injuries and a ...

People who took the daily pill orforglipron lost 12 percent of body weight on average after 72 weeks, according to clinical trial results from Lilly.

Drugmaker Eli Lilly says after successful results in a phase 3 clinical trial, it expects to submit a GLP-1 weight loss pill ...

The new targeted pipeline will advance Nxera’s oral GLP-1 agonists, novel GPCR targets, and structure-based drug design to ...

Eli Lilly's experimental oral pill, orforglipron, shows promise in obesity treatment, with participants experiencing an ...

GLP-1 weight-loss drugs have already taken the Europe storm, altering consumer eating habits. Even the eating habits of GLP-1 ...

A considerable proportion of adolescents and young adults eligible for glucagon-like peptide 1 receptor agonists (GLP-1 RAs) are uninsured.

Overview As demand for GLP-1 drugs continues to skyrocket, federal and state agencies are turning their attention to the GLP-1 market and ramping up efforts to address the perceived risks associated ...